GeneDx (WGS) had the highest return in April 2024 by a mid-cap US stock, returning 87.6%.

ASSET	MONTH	% RETURN
GeneDx (WGS)	April 2024	87.58%
Loar (LOAR)	April 2024	86.86%
Immunitybio (IBRX)	April 2024	49.35%
Regencell Bioscience (RGC)	April 2024	38.01%
Nextnav Acquisition (NN)	April 2024	35.97%
Semtech (SMTC)	April 2024	31.91%
Perpetua Resources (PPTA)	April 2024	29.08%
Grupo Financiero Galicia SA ADR (GGAL)	April 2024	27.38%
TransMedics (TMDX)	April 2024	27.19%
BW LPG (BWLP)	April 2024	26.01%
Impinj (PI)	April 2024	24.18%
GDS (GDS)	April 2024	20.53%
Victory Capital (VCTR)	April 2024	19.47%
Argan (AGX)	April 2024	19.33%
Dave (DAVE)	April 2024	18.76%
Hudbay Minerals (HBM)	April 2024	18.59%
Alvotech (ALVO)	April 2024	18.37%
SSR Mining (SSRM)	April 2024	18.06%
Turkcell Iletisim Hizmetleri AS (TKC)	April 2024	17.99%
Fortuna Silver Mines (FSM)	April 2024	17.92%
Ardagh Metal Packaging (AMBP)	April 2024	17.91%
Oscar Health (OSCR)	April 2024	17.6%
Revolution Medicines (RVMD)	April 2024	16.21%
Manchester United (MANU)	April 2024	16.13%
Transportadora de Gas del Sur SA ADR (TGS)	April 2024	15.81%

Mid-cap stocks are treated as having a market cap between $2B and $10B.